Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

Leukemia

Volumn 27, Issue 10, 2013, Pages 2084-2086

  Barbui, T ^a   Carobbio, A ^a   Finazzi, G ^a   Guglielmelli, P ^b   Salmoiraghi, S ^a   Rosti, V ^c   Rambaldi, A ^a   Vannucchi, A M ^b   Barosi, G ^c  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD CHEMISTRY; BLOOD SAMPLING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CLINICAL PRACTICE; CYTOREDUCTIVE SURGERY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM; HAZARD RATIO; HUMAN; INFLAMMATION; KARYOTYPING; LABORATORY TEST; LETTER; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; OXIDATIVE STRESS; POLYCYTHEMIA VERA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SCORING SYSTEM; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885613426     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.207     Document Type: Letter

References (14)

1. Vainchenker W, Favale F. Myelofibrosis, JAK2 inhibitors and erythropoiesis. Leukemia 2013; 27: 1219-1223.
2. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
3. Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012; 30: 2981-2987.
4. Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88: 141-150.
5. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761.
6. Poletto V, Rosti V, Villani L, Catarsi P, Carolei A, Campanelli R et al. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood 2012; 120: 3112-3117.
7. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
8. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
9. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011; 96: 315-318.
10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
11. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2008; 22: 437-438.
12. Harrell Jr. FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
13. Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 2012; 26: 1439-1441.
14. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 2013; 37: 214-220.